Skip to content


Entresto, Neparvis (sacubitril) is a small molecule pharmaceutical. Sacubitril was first approved as Entresto on 2015-07-07. It has been approved in Europe to treat heart failure. Entresto's patents are valid until 2036-05-09 (FDA).
Trade Name Entresto, Neparvis
Common Name Sacubitril
Indication heart failure
Drug Class Endopeptidase inhibitors
Get full access now